NASDAQ:SHPG - Shire Stock Price, Price Target & More

$160.05 +1.68 (+1.06 %)
(As of 04/26/2018 11:54 AM ET)
Previous Close$158.37
Today's Range$159.52 - $162.92
52-Week Range$123.73 - $192.15
Volume1.03 million shs
Average Volume1.52 million shs
Market Capitalization$49.83 billion
P/E Ratio10.56
Dividend Yield0.64%
Beta1.31

About Shire (NASDAQ:SHPG)

Shire logoShire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SHPG
CUSIPN/A
Phone353-1609-6000

Debt

Debt-to-Equity Ratio0.46%
Current Ratio0.97%
Quick Ratio0.55%

Price-To-Earnings

Trailing P/E Ratio10.56
Forward P/E Ratio10.52
P/E Growth1.29

Sales & Book Value

Annual Sales$15.16 billion
Price / Sales3.21
Cash Flow$22.1676 per share
Price / Cash7.22
Book Value$119.43 per share
Price / Book1.34

Profitability

EPS (Most Recent Fiscal Year)$15.15
Net Income$4.27 billion
Net Margins28.17%
Return on Equity14.19%
Return on Assets6.86%

Miscellaneous

Employees23,044
Outstanding Shares303,950,000

How to Become a New Pot Stock Millionaire

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire declared a semiannual dividend on Friday, February 16th. Investors of record on Friday, March 9th will be paid a dividend of $0.8937 per share on Tuesday, April 24th. This represents a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. This is a positive change from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire (NASDAQ:SHPG) released its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, topping the consensus estimate of $3.86 by $0.12. The biopharmaceutical company earned $4.14 billion during the quarter. Shire had a net margin of 28.17% and a return on equity of 14.19%. The business's revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.37 earnings per share. View Shire's Earnings History.

When is Shire's next earnings date?

Shire is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Shire.

What guidance has Shire issued on next quarter's earnings?

Shire issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.23. The company issued revenue guidance of $15.4-15.9 billion, compared to the consensus revenue estimate of $15.48 billion.

What price target have analysts set for SHPG?

16 Wall Street analysts have issued 1-year price objectives for Shire's shares. Their forecasts range from $150.00 to $245.00. On average, they expect Shire's stock price to reach $205.00 in the next twelve months. View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:
  • 1. According to Zacks Investment Research, "Sales of Shire’s Mydayis showed promise in the first six months of launch. Also, strong performance of Vyvanse, Cinryze and Elaprase continue to drive its top line. The label expansion of Firazyr in pediatrics and approval of Lyophilized Oncaspar in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. Though the adult ADHD space is one of the largest and fastest growing segments of the market, it is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2018)
  • 2. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018)
  • 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)

Are investors shorting Shire?

Shire saw a drop in short interest in April. As of April 13th, there was short interest totalling 705,730 shares, a drop of 69.4% from the March 30th total of 2,304,496 shares. Based on an average daily volume of 989,027 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.2% of the company's stock are short sold.

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Prof. Andreas Busch Ph.D., Head of R&D, Chief Scientific Officer & Exec. VP (Age 55)

Has Shire been receiving favorable news coverage?

News coverage about SHPG stock has trended positive on Thursday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Shire earned a coverage optimism score of 0.28 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Shire?

Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $160.2840.

How big of a company is Shire?

Shire has a market capitalization of $49.83 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]


MarketBeat Community Rating for Shire (SHPG)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  907 (Vote Outperform)
Underperform Votes:  444 (Vote Underperform)
Total Votes:  1,351
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire (NASDAQ:SHPG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
16 Wall Street analysts have issued ratings and price targets for Shire in the last 12 months. Their average twelve-month price target is $205.00, suggesting that the stock has a possible upside of 28.08%. The high price target for SHPG is $245.00 and the low price target for SHPG is $150.00. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.692.712.572.65
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $205.00$204.00$212.1818$219.3333
Price Target Upside: 28.08% upside53.02% upside34.90% upside58.66% upside

Shire (NASDAQ:SHPG) Consensus Price Target History

Price Target History for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/22/2018Royal Bank of CanadaSet Price TargetBuy$186.00LowView Rating Details
4/19/2018B. RileyBoost Price TargetBuy$200.00LowView Rating Details
4/16/2018Cantor FitzgeraldSet Price TargetBuy$222.00MediumView Rating Details
3/28/2018Bank of AmericaReiterated RatingBuyHighView Rating Details
2/20/2018SunTrust BanksLower Price TargetBuy$190.00MediumView Rating Details
2/20/2018JPMorgan ChaseReiterated RatingOverweight -> NeutralMediumView Rating Details
2/14/2018Sanford C. BernsteinUpgradeMarket Perform -> OutperformMediumView Rating Details
1/5/2018CowenSet Price TargetBuy$225.00LowView Rating Details
1/3/2018Piper JaffrayReiterated RatingHoldLowView Rating Details
12/20/2017Liberum CapitalReiterated RatingBuy -> HoldMediumView Rating Details
10/30/2017FBR & CoReiterated RatingBuy$201.00N/AView Rating Details
10/8/2017Stifel NicolausReiterated RatingBuy$245.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$196.00MediumView Rating Details
8/11/2017BarclaysDowngradeOverweight -> Equal WeightLowView Rating Details
8/9/2017Jefferies GroupReiterated RatingHold$216.00 -> $206.00LowView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
4/17/2017Goldman SachsBoost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/6/2016UBSDowngradeBuy -> HoldN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/3/2016CitigroupReiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Shire (NASDAQ:SHPG) Earnings History and Estimates Chart

Earnings by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Earnings Estimates

2018 EPS Consensus Estimate: $15.62
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$3.54$4.01$3.81
Q2 20185$3.63$4.13$3.85
Q3 20185$3.71$4.08$3.84
Q4 20185$3.78$4.37$4.12

Shire (NASDAQ SHPG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/20183/31/2018$3.58$3.37$3.7318 billion$3.7660 billionN/AView Earnings Details
2/14/2018n/a$3.86$3.98$4.1449 billionViewN/AView Earnings Details
10/27/20179/30/2017$3.64$3.81$3.6976 billionViewN/AView Earnings Details
8/3/20176/30/2017$3.53$3.73$3.7458 billionViewListenView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.5723 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.7752 billion$3.8061 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.2757 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.0540$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.7160 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.5293 billion$1.5761 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.2146 billion$1.2750 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
10/29/2010Q3 2010$0.98$1.16ViewN/AView Earnings Details
8/4/2010Q2 2010$0.88$1.03ViewN/AView Earnings Details
4/29/2010Q1 2010$0.84$1.01ViewN/AView Earnings Details
2/19/2010Q4 2009$0.58$1.10ViewN/AView Earnings Details
10/30/2009Q3 2009$0.48$0.49ViewN/AView Earnings Details
8/5/2009Q2 2009$0.47$0.60ViewN/AView Earnings Details
4/30/2009Q1 2009$1.08$1.28ViewN/AView Earnings Details
2/19/2009Q4 2008$1.00$1.01ViewN/AView Earnings Details
10/29/2008Q3 2008$0.87$1.17ViewN/AView Earnings Details
7/31/2008Q2 2008$0.75$0.95ViewN/AView Earnings Details
4/25/2008Q1 2008$0.72$0.74ViewN/AView Earnings Details
2/21/2008Q4 2007$0.64$0.94ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Shire (NASDAQ:SHPG) Dividend Information

Shire pays an annual dividend of $1.05 per share, with a dividend yield of 0.66%. SHPG's most recent semiannual dividend payment was Tuesday, April 24. Shire pays out 6.93% of its earnings out as a dividend.
Most Recent Dividend:4/24/2018
Annual Dividend:$1.05
Dividend Yield:0.66%
Payout Ratio:6.93% (Trailing 12 Months of Earnings)
6.90% (Based on This Year's Estimates)
6.44% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/16/2018semiannual$0.89371.33%3/8/20183/9/20184/24/2018
8/11/2017semiannual$0.15270.21%9/7/20179/8/201710/20/2017
2/24/2017$0.77103/8/20173/10/20174/25/2017
8/5/2016$0.13909/7/20169/9/201610/7/2016
2/11/2016$0.66503/9/20163/11/20164/12/2016
7/23/2015$0.12639/2/20159/4/201510/2/2015
2/23/2015semiannual$0.57270.48%3/11/20153/13/20154/14/2015
8/4/2014semiannual$0.11490.09%9/3/20149/5/201410/3/2014
2/20/2014semiannual$0.50790.61%3/5/20143/7/20144/8/2014
7/29/2013semiannual$0.090.16%9/4/20139/6/201310/3/2013
2/19/2013semiannual$0.43800.92%3/6/20133/8/20134/9/2013
(Data available from 1/1/2013 forward)

Insider Trades

Shire (NASDAQ SHPG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 19.49%
Insider Trading History for Shire (NASDAQ:SHPG)
Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ SHPG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Shire (NASDAQ SHPG) News Headlines

Source:
DateHeadline
Shire (SHPG) Issues FY18 Earnings GuidanceShire (SHPG) Issues FY18 Earnings Guidance
www.americanbankingnews.com - April 26 at 9:26 AM
Shire profit rises on higher sales, backs outlookShire profit rises on higher sales, backs outlook
www.marketwatch.com - April 26 at 8:13 AM
Bid target Shire grows earnings six percent, holds cautious outlookBid target Shire grows earnings six percent, holds cautious outlook
finance.yahoo.com - April 26 at 8:13 AM
[$$] Shire Q1 sales rise 7% driven by immunology and new treatments[$$] Shire Q1 sales rise 7% driven by immunology and new treatments
finance.yahoo.com - April 26 at 8:13 AM
Shire plc : 1st Quarter ResultsShire plc : 1st Quarter Results
feeds.benzinga.com - April 26 at 7:57 AM
Traders Buy High Volume of Shire Put Options (SHPG)Traders Buy High Volume of Shire Put Options (SHPG)
www.americanbankingnews.com - April 26 at 6:34 AM
Shire (SHPG) Receives Average Recommendation of "Buy" from BrokeragesShire (SHPG) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 25 at 1:36 PM
Shire (SHPG) Expected to Announce Earnings of $3.58 Per ShareShire (SHPG) Expected to Announce Earnings of $3.58 Per Share
www.americanbankingnews.com - April 25 at 1:24 PM
Stock Slide, Takeda and Shire, Facebook Reshuffle: CEO Daily for April 25, 2018Stock Slide, Takeda and Shire, Facebook Reshuffle: CEO Daily for April 25, 2018
fortune.com - April 25 at 8:14 AM
FTSE 100 scores 6th win in a row as oil shares, Shire rallyFTSE 100 scores 6th win in a row as oil shares, Shire rally
www.marketwatch.com - April 25 at 8:14 AM
Shire earnings preview: Takeda bid in focusShire earnings preview: Takeda bid in focus
www.marketwatch.com - April 25 at 8:14 AM
Stocks to watch: Metro Bank, Shire, Whitbread, Boohoo, VW, KeringStocks to watch: Metro Bank, Shire, Whitbread, Boohoo, VW, Kering
www.ft.com - April 25 at 8:14 AM
Shire willing to back $64 billion Takeda bid, market signals doubtsShire willing to back $64 billion Takeda bid, market signals doubts
finance.yahoo.com - April 25 at 8:14 AM
Benzingas Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlos Woes Abound, Earnings Fail to Boost AmgenBenzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen
feeds.benzinga.com - April 25 at 8:11 AM
Reuters: Breakthrough means likely Shire/Takeda deal as soon as tomorrowReuters: Breakthrough means likely Shire/Takeda deal as soon as tomorrow
seekingalpha.com - April 24 at 9:03 PM
Shire and Takeda to announce preliminary deal Wednesday after breakthrough in merger talks: Reuters, citing sourcesShire and Takeda to announce preliminary deal Wednesday after breakthrough in merger talks: Reuters, citing sources
www.cnbc.com - April 24 at 6:13 PM
BTIG: Shire may seek topping bid after latest from TakedaBTIG: Shire may seek topping bid after latest from Takeda
seekingalpha.com - April 24 at 3:28 PM
BRIEF-Takeda Is Said To Near Preliminary Agreement To Buy Shire- BloombergBRIEF-Takeda Is Said To Near Preliminary Agreement To Buy Shire- Bloomberg
www.reuters.com - April 24 at 8:15 AM
BRIEF-Shire Says Received Revised Proposal From Takeda On Possible Offer, Says Considering Its PositionBRIEF-Shire Says Received Revised Proposal From Takeda On Possible Offer, Says Considering Its Position
www.reuters.com - April 24 at 8:15 AM
Stocks to watch: William Hill, Shire, Vectura, Qinetiq, AMS, AppleStocks to watch: William Hill, Shire, Vectura, Qinetiq, AMS, Apple
www.ft.com - April 24 at 8:15 AM
Shire plc : Statement re revised proposalShire plc : Statement re revised proposal
globenewswire.com - April 24 at 8:15 AM
Takedas Finances Could Take Big Hit If Shire Deal SucceedsTakeda's Finances Could Take Big Hit If Shire Deal Succeeds
finance.yahoo.com - April 24 at 8:15 AM
With deadline looming, Takeda nears agreement to buy Shire, says BloombergWith deadline looming, Takeda nears agreement to buy Shire, says Bloomberg
finance.yahoo.com - April 24 at 8:15 AM
Takeda Near Preliminary Agreement to Acquire ShireTakeda Near Preliminary Agreement to Acquire Shire
finance.yahoo.com - April 24 at 8:15 AM
Shire receives new bid from Takeda as takeover deadline loomsShire receives new bid from Takeda as takeover deadline looms
finance.yahoo.com - April 24 at 8:15 AM
Shire and Takeda close to a deal - BloombergShire and Takeda close to a deal - Bloomberg
seekingalpha.com - April 24 at 7:01 AM
Shire (SHPG) Upgraded at Zacks Investment ResearchShire (SHPG) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 23 at 2:58 PM
Shire (SHPG) Given a $186.00 Price Target by Royal Bank of Canada AnalystsShire (SHPG) Given a $186.00 Price Target by Royal Bank of Canada Analysts
www.americanbankingnews.com - April 23 at 9:18 AM
Japans Takeda sweetens $62 billion Shire offerJapan's Takeda sweetens $62 billion Shire offer
www.reuters.com - April 22 at 8:14 AM
Shire Rebuff May Not Dim Takedas Appetite for $60 Billion DealShire Rebuff May Not Dim Takeda's Appetite for $60 Billion Deal
finance.yahoo.com - April 22 at 8:14 AM
Shire (SHPG) Turns Down Takedas Third Buyout PropositionShire (SHPG) Turns Down Takeda's Third Buyout Proposition
finance.yahoo.com - April 22 at 8:14 AM
Takedas considering turning up the heat on its bid for Shire (TKPYY, SHPG)Takeda's considering turning up the heat on its bid for Shire (TKPYY, SHPG)
www.businessinsider.com - April 21 at 8:16 AM
Takeda Adds More Cash in Boosting Shire Bid Over $60 BillionTakeda Adds More Cash in Boosting Shire Bid Over $60 Billion
www.bloomberg.com - April 21 at 8:16 AM
[$$] Takeda Increases Takeover Proposal for Drug Rival Shire[$$] Takeda Increases Takeover Proposal for Drug Rival Shire
finance.yahoo.com - April 21 at 8:16 AM
Takeda sweetens offer for Shire to £47/shareTakeda sweetens offer for Shire to £47/share
seekingalpha.com - April 20 at 10:28 AM
Brainstorm Health: The Gene Testing Perk, Shire Takeover Drama, Marijuana-Based Epilepsy DrugBrainstorm Health: The Gene Testing Perk, Shire Takeover Drama, Marijuana-Based Epilepsy Drug
fortune.com - April 20 at 8:20 AM
Rare Disease Drug Maker Shires Stock Spikes Amid Bidding War Between Allergan and TakedaRare Disease Drug Maker Shire's Stock Spikes Amid Bidding War Between Allergan and Takeda
fortune.com - April 20 at 8:20 AM
Stocks to watch: Shire, Reckitt, Hammerson, Ericsson, EsureStocks to watch: Shire, Reckitt, Hammerson, Ericsson, Esure
www.ft.com - April 20 at 8:20 AM
Third Time Unlucky for Takeda and ShireThird Time Unlucky for Takeda and Shire
www.wsj.com - April 20 at 8:20 AM
Losing direction: Allergan investors are unhappy after a wild 4-hour takeover drama'Losing direction': Allergan investors are unhappy after a wild 4-hour takeover drama
www.businessinsider.com - April 20 at 8:20 AM
Shire Rebuff May Not Dim Takedas Appetite for a TakeoverShire Rebuff May Not Dim Takeda's Appetite for a Takeover
www.bloomberg.com - April 20 at 8:20 AM
[$$] Shire shares down 3.7% after Allergan rules out bid[$$] Shire shares down 3.7% after Allergan rules out bid
finance.yahoo.com - April 20 at 8:19 AM
Japans Takeda shares drop as investors fret over Shire pursuitJapan's Takeda shares drop as investors fret over Shire pursuit
finance.yahoo.com - April 20 at 8:19 AM
FTSE 100 rises, as pound falls on BOE rate-hike doubtsFTSE 100 rises, as pound falls on BOE rate-hike doubts
finance.yahoo.com - April 20 at 8:19 AM
Takeda slips after Shire rejects $63B offerTakeda slips after Shire rejects $63B offer
seekingalpha.com - April 20 at 5:15 AM
Shire says it rejected Takeda’s first three takeover offers, including $60B bidShire says it rejected Takeda’s first three takeover offers, including $60B bid
www.bizjournals.com - April 19 at 5:44 PM
Takeda Says Shire (SHPG) Rejected GBP 46.50 per Share OfferTakeda Says Shire (SHPG) Rejected GBP 46.50 per Share Offer
www.streetinsider.com - April 19 at 5:44 PM
CNBC: Allergan-Shire Deal Is DOACNBC: Allergan-Shire Deal Is DOA
finance.yahoo.com - April 19 at 5:44 PM
Is Shire plc’s (NASDAQ:SHPG) PE Ratio A Signal To Buy For Investors?Is Shire plc’s (NASDAQ:SHPG) PE Ratio A Signal To Buy For Investors?
finance.yahoo.com - April 19 at 5:44 PM
Shire (SHPG) Comments on Proposals from Takeda PharmaceuticalShire (SHPG) Comments on Proposals from Takeda Pharmaceutical
www.streetinsider.com - April 19 at 5:44 PM

SEC Filings

Shire (NASDAQ:SHPG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Shire (NASDAQ:SHPG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Shire (NASDAQ SHPG) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.